Case report of penile cancer recurrence treated with cetuximab combined with anlotinib

Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first‐line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new c...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Shuang, Liu, Yan‐Yang, Liu, Tao, Zhang, Yu, Luo, De‐Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847399/
https://www.ncbi.nlm.nih.gov/pubmed/35223013
http://dx.doi.org/10.1002/ccr3.5443
_version_ 1784652041656729600
author Dai, Shuang
Liu, Yan‐Yang
Liu, Tao
Zhang, Yu
Luo, De‐Yun
author_facet Dai, Shuang
Liu, Yan‐Yang
Liu, Tao
Zhang, Yu
Luo, De‐Yun
author_sort Dai, Shuang
collection PubMed
description Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first‐line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC.
format Online
Article
Text
id pubmed-8847399
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-88473992022-02-25 Case report of penile cancer recurrence treated with cetuximab combined with anlotinib Dai, Shuang Liu, Yan‐Yang Liu, Tao Zhang, Yu Luo, De‐Yun Clin Case Rep Case Reports Penile squamous cell carcinoma with pelvic lymph node metastases/recurrence has a poor prognosis. We reported a case with recurrent pSCC was administered cetuximab and anlotinib after failure of first‐line treatment and achieved an effective response. Cetuximab combined with anlotinib may be a new choice for relapsed pSCC. John Wiley and Sons Inc. 2022-02-15 /pmc/articles/PMC8847399/ /pubmed/35223013 http://dx.doi.org/10.1002/ccr3.5443 Text en © 2022 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Reports
Dai, Shuang
Liu, Yan‐Yang
Liu, Tao
Zhang, Yu
Luo, De‐Yun
Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title_full Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title_fullStr Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title_full_unstemmed Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title_short Case report of penile cancer recurrence treated with cetuximab combined with anlotinib
title_sort case report of penile cancer recurrence treated with cetuximab combined with anlotinib
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847399/
https://www.ncbi.nlm.nih.gov/pubmed/35223013
http://dx.doi.org/10.1002/ccr3.5443
work_keys_str_mv AT daishuang casereportofpenilecancerrecurrencetreatedwithcetuximabcombinedwithanlotinib
AT liuyanyang casereportofpenilecancerrecurrencetreatedwithcetuximabcombinedwithanlotinib
AT liutao casereportofpenilecancerrecurrencetreatedwithcetuximabcombinedwithanlotinib
AT zhangyu casereportofpenilecancerrecurrencetreatedwithcetuximabcombinedwithanlotinib
AT luodeyun casereportofpenilecancerrecurrencetreatedwithcetuximabcombinedwithanlotinib

Ejemplares similares